|
Volume 4 No. 4, January 2009 |
||
|
The Role of Naturally
Activated Nigella Sativa (Rabicabir) in Original Baraka Capsules as
an Effective Antiviral Drug in Hepatitis C Virus and Its
Complications Department of Clinical Pharmaceutics, Laboratoire de Biopharmacie, Université d’Auvergne, Clermont-Ferrand, France(1). Department of organic chemistry, Faculty of Pharmacy, Helwan University, Egypt(2). Department of pharmaceutics Faculty of Pharmacy, Kanal Suez University, Egypt(3). Department of clinical pharmacy Faculty of Pharmacy, Helwan University, Egypt & Department of Hepatology, Faculty of Medicine, Menofeya University(4). Department of gastroenterology, Faculty of Medicine, Alexandria University(5). Department of internal medicine Faculty of Medicine, Alexandria University(6). Department of internal medicine, Faculty of Medicine, Cairo, Cairo University(7).
Tanta Med. Sc. J 2009; 4(1):16-29
Aim: The study is aiming to determine the efficacy and tolerance
of the new invented naturally activated Nigella Sativa (Rabicabir)
that exists in Original Baraka capsules as a basic antiviral
treatment of hepatitis C virus and its complications. Patients &
Methods: One hundred patients with chronic active hepatitis C virus
confirmed Histopathologicaly and associated with high HCV-RNA PCR
quantitatively were treated with the new invented drug extract
(registered as an invented drug in Academy of scientific research
and technology (patent office) of ministry of state for scientific
research, Egypt under the name of Malak Liver (Rabicabir) capsules;
patent number 200605216 and developed in France through "Laboratoire
d’Innovation in design and development drugs delivery devices"
located in Clermont-ferrand. Medical statistical analyses of random
100 patients of HCV were treated by the new invented drug in
multi-hepatological centres all over Egypt in the period from
January 2002 to October 2005. Results: Laboratory investigations
found that; regarding liver function tests, Rabicabir capsules show
normalized liver enzymes in all patients. Regarding HCV-RNA PCR
quantitative assessment, 70 % of Rabicabir treated patients had
complete remission of HCV viraemia while 30% of Rabicabir treated
patients had partial remission with significant improvement of HCV
viraemia level. Radiological investigations found that;
Ultrasonography abdomen examination for liver, Rabicabir capsules
show significant improvement of liver condition, size and
parenchymal affection in 67.5% of patients. For portal vein
diameter, Rabicabir capsules show significant improvement and
normalization of portal vein diameter and pressure in all patients.
For spleen examination, Rabicabir capsules show significant
improvement of spleen condition, size and activity in 96% of
patients. On the level of liver biopsy and histopathological
examination, regarding HCV chronic hepatitis activity scoring, 69%
Rabicabir treated patients improved to mild HCV activity score while
1% of Rabicabir treated patients showed complete assisted activity,
yet 30% showed less improvement. On the level of general conditions
of patients, 98% of patients had general condition improvement
(improvement of effort, no fatigue, no exhaustion, no weakness,
increase the appetite, weight regain, disappearance of nausea
sensation, significant decrease of daily bleeding from nose, gum and
mouth, significant elevation of Prothrombin secretion, disappearance
of spasms sensation in the right hand side of the abdomen,
disappearance of dark pigmentation on the face and legs, and gradual
disappearance of pale yellow colour of eye and nails, indicating
that liver starts to work again. On the level of liver fibrosis(40-
45) grading system, 10% of treated patients got significant
improvement and had very minimal fibrosis, 65% of treated patients
improved and had mild liver fibrosis, while 25% of treated patients
showed minimal improvement of liver fibrosis. The new invented drug
is given to HCV patients with their approval consent in a dose of
three grams per day after meals for a period ranged from 24-48
months according to HCV viraemia severity and liver condition.
Conclusion: The new invented drug Rabicabir capsules is safe without
any adverse reactions and has very good tolerability. |
||
|
|
||
